Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004041 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Study locations
NCT00004041: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00004041 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004041, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8
- Study locations
Study Summary
RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent malignant gliomas.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL Ad5CMV-p53 gene
Study Locations (8)
Texas
- Simmons Cancer Center - Dallas - Dallas
- University of Texas - MD Anderson Cancer Center - Houston
- University of Texas Health Science Center at San Antonio - San Antonio
California
- UCSF Cancer Center and Cancer Research Institute - San Francisco
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Wisconsin
- University of Wisconsin Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02-25 |
| Est. Completion | 2003-07-01 |
| Phase | Phase 1 |
What the finished NCT00004041 record still lists
NCT00004041 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which conventional surgery is the first listed.
NCT00004041 lists 8 locations in 6 states (Texas, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00004041 about?
NCT00004041 is a clinical study titled "Gene Therapy in Treating Patients With Recurrent Malignant Gliomas". RATIONALE: Inserting the gene for adenovirus p53 into a person's tumor may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have recurrent malignant gliomas.
What is the current status of trial NCT00004041?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-02-25. Estimated completion is 2003-07-01.
What conditions does trial NCT00004041 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00004041?
The interventions under investigation include: conventional surgery (PROCEDURE), Ad5CMV-p53 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004041?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004041 being conducted?
This trial has 8 study locations across California, Massachusetts, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI